Skip to content

Effects of Curcumin on Vascular Reactivity

Effects of Curcumin Loading Dose on Vascular Reactivity of Healthy Middle-aged Smokers

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01543386
Acronym
CURCUMIN
Enrollment
21
Registered
2012-03-05
Start date
2012-02-01
Completion date
2012-04-01
Last updated
2026-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteers (Middle-aged Smokers)

Keywords

Polyphenol, Curcumin, Endothelium, vascular, Endothelium-dependant relaxing factor, Smoking, Transcriptome

Brief summary

The aim of this study is to determine if an oral loading-dose of curcumin can improve vascular endothelium reactivity in patients with moderate cardiovascular risk

Detailed description

The aim of this study is to determine if an oral loading-dose of curcumin can improve vascular endothelium reactivity in patients with moderate cardiovascular risk

Interventions

DRUGCurcumin

The aim of this study is to determine if an oral loading-dose of curcumin can improve vascular endothelium reactivity in patients with moderate cardiovascular risk

Sponsors

University Hospital, Clermont-Ferrand
Lead SponsorOTHER
Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
CollaboratorOTHER
Association Régionale de Cardiologie d'Auvergne
CollaboratorUNKNOWN
ARDEC Association de Recherche de Développement et d'Enseignement de la Cardiologie
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
50 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* 50 to 70 year-old volunteers * smokers

Exclusion criteria

* treated hypertension * treated hypercholesterolemia * chronic disease * vegetarian or other unusual diets * chronic alcoholism

Design outcomes

Primary

MeasureTime frame
Changes in brachial Flow Mediated Dilatationat Visit 1 (Day 0) and visit 2 (Day3/day5)

Secondary

MeasureTime frame
Changes in fingertip arterial tonometryat visit 1 (day 0) and visit 2 (day3/day5)
Modifications of leukocytes transcriptomeat visit 1 (day 0) and visit 2 (day3/day 5)

Countries

France

Contacts

PRINCIPAL_INVESTIGATORJean-René LUSSON

University Hospital, Clermont-Ferrand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 6, 2026